HCWB

HCW Biologics Inc. (HCWB) | Rumor.io

HCW Biologics

HCWB

Attention (50-day avg)0%

Attention rank (50-day avg)#2,342

Bullish sentiment (50-day avg)81%

Price to earnings ratio-0.03

Market capitalization3.3M

Earnings per share-16.6

Dividend yield (TTM)—

Revenue (annual)54.2K

Net income (annual)-8M

Social

What share of all stock conversation is about HCWB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 24

$HCWB is pricing a $1.5 million private placement with an existing institutional investor, comprising 903,614 units with pre-funded warrants and common stock purchase warrants.
The stock has been halted multiple times, with a significant price increase of 43% on one occasion, and has been defended by buyers at the $1.61 level as momentum improves.
Technical analysis suggests a possible high-volume breakout above $1.83, which could accelerate momentum toward $2+, and a 4-hour chart wedge is forming with room for liquidity up to $2.7.

Generated by AI

Sentiment

Of the messages about HCWB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	90.79% -9.21	91.76% +43.62	82.42% -3.12
Bearish	—	9.21% +9.21	8.24% -43.62	17.58% +3.12

Bullish· Sep 24

$HCWB has a strong potential for a significant price increase if retail investors jump on it, as indicated by the enthusiastic posts.
The company's recent private placement news, which involved a $1.5 million financing, could lead to a price increase, with some posts suggesting a move towards $2.00–$2.15.
Insider buying at $3 in July, followed by a small private placement, could be a short-term opportunity for investors, with some posts predicting a price increase to $3.50.

Bearish· Jun 2

$HCWB's shares available for shorting have dried up, indicating a lack of buying pressure.
The company's short interest is high, with days to cover exceeding 2 days, suggesting a significant short position.
Insiders and institutional investors purchased shares at $1.40 before a potential vote on June 15th, which may have been an attempt to shore up the stock before a short influx.

Generated by AI

Topics

Of the messages about HCWB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	82.35%	91.89%	13.16%
Analysts	—	0%	0%	0.9%
Earnings	—	0%	0%	1.28%
Macro	—	0%	0%	76.45%
Technical Analysis	—	17.65%	8.11%	8.06%
Controversies	—	0%	0%	0.15%

Announcements· May 15

HCW Biologics Inc. (HCWB) reported a 493% surge in Q1 revenue to $6.53M, driven by a $6.5M nonrefundable upfront license fee from Trimmune.
The company's net income swung to $3.47M from a loss, supported by reduced operating expenses and a $3.5M in-kind payment from Trimmune.
HCWB shares surged 343% on the Q1 results, with the company also making progress on its Phase 1 HCW9302 alopecia study.

Technical Analysis· May 22

$HCWB is trading in a bullish setup with a potential pullback to 3.46 support, providing a tight risk level with clear upside.
The daily chart shows a bullish case with a key support level at 1.8-1.95 and a potential test of 3.2-3.45, with the stock currently trading at 3.20.
$HCWB is forming a cup and handle pattern, with a potential breakout above 3.70, and has a high likelihood of bouncing hard from the current dip due to low volume.

Generated by AI

Community

Of the messages about HCWB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	22.45%	26.25%	9.41%
Newcomers	—	77.55%	73.75%	90.59%

Regulars· Sep 24

HCW Biologics Inc. ($HCWB) priced a $1.5 million private placement, selling 903,614 units at $1.6599 each, including a pre-funded warrant and a common warrant pending stockholder approval.
The company's product, Drug M, has received FDA approval for its New Drug Application (NDA) and is in a Phase 3 trial for epidemic meningitis, with the European Medicines Agency (EMA) having a pending Marketing Authorization Application (MAA).
The private placement news has led to speculation that $HCWB could reverse off its dips, with potential resistance levels at $2.30/$2.70, and a break above $3.00 being seen as a potential catalyst for a move.

Newcomers· Sep 24

Newcomers are focusing on the potential for a high-flying price move if retail investors jump on HCW Biologics Inc. ($HCWB).
The company's private placement of a $1.5 million financing deal with an institutional investor is seen as a positive development, with some users expecting a potential decrease in ownership for existing investors.
A short setup on $HCWB has been validated, with a 50.6% price increase today, and a relative volume of 13.5x, with $3 million in trading activity.

Generated by AI

HCW Biologics Inc. (NASDAQ:HCWB) has entered into an exclusive distribution agreement with Akron Biotech covering HCW11-006, its multi-cytokine fusion molecule designed for use as a reagent in CAR-T cell manufacturing.

21d agoYahoo Finance

HCW Biologics signs distribution deal with Akron Biotech

21d agoInvesting.com

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial compan

22d agoYahoo Finance

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8+ T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel

1mo agoYahoo Finance

HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion

1mo agoInvesting.com

Also Discussed

Investors talking about HCWB also mention

#	Name	Attention
1	Snail Inc. Class A Common StockSNAL	0%0
2	Inno Holdings Inc.INHD	0%new
3	Gaxos.ai Inc.GXAI	0%0
4	MetaVia Inc.MTVA	0%0
5	Generation Income Properties Inc.GIPR	0%0
6	Silexion Therapeutics Corp.SLXN	0.03%-0.01
7	P3 Health Partners Inc. Class A Common StockPIII	0%new
8	Stak Inc. Class A Ordinary SharesSTAK	0%0
9	TCTM - TCTM Kids IT Education Inc.	——
10	Tharimmune Inc.THAR	0%new

HCW Biologics Inc.

Healthcare
Biotechnology

HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for diseases driven by chronic, low-grade inflammation. The company’s current work centers on fusion protein-based drug candidates designed to address autoimmune disorders, cancer, and age-related inflammatory conditions. Its research programs use proprietary platforms to create biologic molecules intended to modulate immune responses and target pathways linked to inflammaging and senescence. HCW Biologics operates in the biotechnology sector, with a business model built around discovery, preclinical development, and early-stage clinical testing of its therapeutic pipeline. Based in Miramar, Florida and founded in 2018, HCW Biologics aims to advance treatments that may have applications across oncology, immunology, and other inflammatory disease areas.

Website

Location

2929 North Commerce Parkway

Miramar, FL, 33025

United States

Social

What share of all stock conversation is about HCWB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 24

$HCWB is pricing a $1.5 million private placement with an existing institutional investor, comprising 903,614 units with pre-funded warrants and common stock purchase warrants.
The stock has been halted multiple times, with a significant price increase of 43% on one occasion, and has been defended by buyers at the $1.61 level as momentum improves.
Technical analysis suggests a possible high-volume breakout above $1.83, which could accelerate momentum toward $2+, and a 4-hour chart wedge is forming with room for liquidity up to $2.7.

Generated by AI

Sentiment

Of the messages about HCWB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	90.79% -9.21	91.76% +43.62	82.42% -3.12
Bearish	—	9.21% +9.21	8.24% -43.62	17.58% +3.12

Bullish· Sep 24

$HCWB has a strong potential for a significant price increase if retail investors jump on it, as indicated by the enthusiastic posts.
The company's recent private placement news, which involved a $1.5 million financing, could lead to a price increase, with some posts suggesting a move towards $2.00–$2.15.
Insider buying at $3 in July, followed by a small private placement, could be a short-term opportunity for investors, with some posts predicting a price increase to $3.50.

Bearish· Jun 2

$HCWB's shares available for shorting have dried up, indicating a lack of buying pressure.
The company's short interest is high, with days to cover exceeding 2 days, suggesting a significant short position.
Insiders and institutional investors purchased shares at $1.40 before a potential vote on June 15th, which may have been an attempt to shore up the stock before a short influx.

Generated by AI

Topics

Of the messages about HCWB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	82.35%	91.89%	13.16%
Analysts	—	0%	0%	0.9%
Earnings	—	0%	0%	1.28%
Macro	—	0%	0%	76.45%
Technical Analysis	—	17.65%	8.11%	8.06%
Controversies	—	0%	0%	0.15%

Announcements· May 15

HCW Biologics Inc. (HCWB) reported a 493% surge in Q1 revenue to $6.53M, driven by a $6.5M nonrefundable upfront license fee from Trimmune.
The company's net income swung to $3.47M from a loss, supported by reduced operating expenses and a $3.5M in-kind payment from Trimmune.
HCWB shares surged 343% on the Q1 results, with the company also making progress on its Phase 1 HCW9302 alopecia study.

Technical Analysis· May 22

$HCWB is trading in a bullish setup with a potential pullback to 3.46 support, providing a tight risk level with clear upside.
The daily chart shows a bullish case with a key support level at 1.8-1.95 and a potential test of 3.2-3.45, with the stock currently trading at 3.20.
$HCWB is forming a cup and handle pattern, with a potential breakout above 3.70, and has a high likelihood of bouncing hard from the current dip due to low volume.

Generated by AI

Community

Of the messages about HCWB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	22.45%	26.25%	9.41%
Newcomers	—	77.55%	73.75%	90.59%

Regulars· Sep 24

HCW Biologics Inc. ($HCWB) priced a $1.5 million private placement, selling 903,614 units at $1.6599 each, including a pre-funded warrant and a common warrant pending stockholder approval.
The company's product, Drug M, has received FDA approval for its New Drug Application (NDA) and is in a Phase 3 trial for epidemic meningitis, with the European Medicines Agency (EMA) having a pending Marketing Authorization Application (MAA).
The private placement news has led to speculation that $HCWB could reverse off its dips, with potential resistance levels at $2.30/$2.70, and a break above $3.00 being seen as a potential catalyst for a move.

Newcomers· Sep 24

Newcomers are focusing on the potential for a high-flying price move if retail investors jump on HCW Biologics Inc. ($HCWB).
The company's private placement of a $1.5 million financing deal with an institutional investor is seen as a positive development, with some users expecting a potential decrease in ownership for existing investors.
A short setup on $HCWB has been validated, with a 50.6% price increase today, and a relative volume of 13.5x, with $3 million in trading activity.

Generated by AI

HCW Biologics

Social

Sep 24

Bullish· Sep 24

Bearish· Jun 2

Announcements· May 15

Technical Analysis· May 22

Regulars· Sep 24

Newcomers· Sep 24

HCW Biologics prices $1.5M private placement offering

HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent

HCW Biologics signs distribution deal with Akron Biotech

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion

Also Discussed

HCW Biologics Inc.

Company Information

Location

HCW Biologics prices $1.5M private placement offering

HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent

HCW Biologics signs distribution deal with Akron Biotech

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion

Also Discussed

Social

Sep 24

Bullish· Sep 24

Bearish· Jun 2

Announcements· May 15

Technical Analysis· May 22

Regulars· Sep 24

Newcomers· Sep 24